Novartis Exjade Review Complicated By Use Of SQUID To Measure Iron Levels
This article was originally published in Pharmaceutical Approvals Monthly
Use of a superconducting quantum interference device (SQUID) is "inadequate" to accurately measure liver iron concentration, FDA determined in its review of Novartis’ oral iron chelating agent Exjade.
You may also be interested in...
Novartis plans three NME filings in 2005, including first oral VEGF agent, firm says during Jan. 20 R&D day. PTK787 has blockbuster potential in colorectal cancer, Novartis says. Nine more NME filings are scheduled for next two years
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011